Pathology; Neuropathology; CNS tumors
The main focus of our unit is the diagnosis and treatment of primary and metastatic brain tumors through integrated and multidisciplinary approaches. This clinical mission is matched by research activities aimed at evaluating novel prognostic and predictive markers as well new therapeutic options for patients with central nervous system neoplasms.
Contribution of the RISEbrain project:
Our unit in Turin, Italy will be involved in both the clinical and translation tasks of the project. Concerning the clinical activities, a clinical trial to evaluate the efficacy of silibinin for brain metastasis treatment will be carried out within the Neuro-oncology Unit of our University Hospital. This trial will be critical to help enable novel therapeutic options for a challenging and increasing patient population with an unfavorable outcome. Moreover, the data collected within this clinical trial will allow to elucidate the mechanisms associated with brain metastasis growth and recurrence. Regarding the translational research activities, we will collect a large series of retrospective and prospective brain metastases samples to perform comprehensive molecular profiling, together with the RISEbrain project’s partners. In particular, our team will perform single cell transcriptomic profiling to investigate the interactions between tumor and microenvironment cell populations including immune and CNS resident cells.
Project partners: Pathology unit, Department of Medical Sciences, University of Turin, Italy and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK
A controlled, randomized, double-blind clinical trial to evaluate the efficacy of SILbinin versus placebo to prevent recurrence after surgical resection of a single brain METastasis from non-small cell lung carcinoma or breast carcinoma
Journal of Neuropathology & Experimental Neurology 2019 Mar 1;78(3):248-256
Acta Neuropathologica 2019 May;137(5):837-846
The Journal of Molecular Diagnostics 2021 Apr 19:S1525-1578(21)00090-8